HER2-Positive Right Breast Cancer With Complete Response Before Bilateral Mastectomy
This breast cancer diagnosis at a glance
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- ER negative, PR negative, HER2 positive, Ki67 67%
- Sex
- female
- Treatment
- chemotherapy, targeted therapy and surgery
- Outcome
- Responding Well
Treatment course, step by step
- She received neoadjuvant carboplatin-based chemotherapy with Herceptin.
- She then underwent bilateral total mastectomy with right sentinel lymph-node biopsy and immediate reconstruction.
What happened, in summary
A 59-year-old woman was evaluated for right-sided breast pain. Imaging found a roughly 3 cm right-breast mass, and biopsy confirmed grade 3 invasive ductal carcinoma. The tumor was ER negative, PR negative and HER2 positive, with Ki67 at 67%. A right axillary-node biopsy showed no malignancy. She received neoadjuvant carboplatin-based chemotherapy with Herceptin. After treatment, bilateral mammography showed complete resolution of the known right-breast mass. At her request, she then underwent bilateral total mastectomy, right sentinel lymph-node biopsy and immediate reconstruction. Pathology found no residual tumor in the right-breast specimen, and the right sentinel lymph node was negative. This supports a strong treatment response for the right-sided cancer. The operation unexpectedly found a separate cancer in the left breast with a different receptor profile. The right-sided cancer itself showed no residual tumor after treatment and surgery.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- HER2 Positive Breast Cancer 136 stories
- Carboplatin for Breast Cancer 73 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer